Browse the corpus

Ixazomib, a second-generation proteasome inhibitor, emerges as a pivotal therapeutic option for managing multiple myeloma. Addressing the needs of multiple myeloma patients, this activity discusses ixazomib's mechanism of action, indications, and contraindications. The comprehensive discussion extends to ixazomib's adverse event profile and other critical facets, ensuring the members of an interprofessional team can navigate the complexities inherent in managing multiple myeloma and its associated conditions. The collaborative emphasis throughout underscores the indispensable nature of interprofessional teamwork in managing these intricate hematological conditions and the need to enhance the team's knowledge and proficiency in leveraging ixazomib to benefit individuals affected by multiple myeloma and its related complexities. Objectives: Identify appropriate patient profiles and disease contexts where ixazomib is indicated for multiple myeloma treatment. Differentiate between ixazomib and other therapeutic options, understanding its unique mechanisms, benefits, and potential drawbacks. Implement evidence-based dosing strategies and treatment plans for ixazomib, ensuring proper administration and adherence. Implement plans with interprofessional teams, including oncologists, pharmacists, and nurses, to optimize ixazomib therapy within the broader patient care strategy. Access free multiple choice questions on this topic.

Some of the toxicities involved with ixazomib include hematological and hepatic toxicities. Hematological toxicities include thrombocytopenia, which was seen primarily during the first 3 months of treatment in the drug approval study. Platelets usually drop after a dose of ixazomib and then rise again before the next treatment cycle. Also, during the study, a small percentage of patients had to be taken off of ixazomib therapy due to thrombocytopenia.[15] As previously discussed, there is also a risk of hepatotoxicity with ixazomib due to different hepatic injuries in patients; liver function monitoring is crucial.[11] Furthermore, unlike other proteasome inhibitors previously reported to cause cardiac toxicity, ixazomib is not known to cause an increase in cardiac events, toxicities, or prolonged QTc interval.[15][17] Ixazomib is less neurotoxic than bortezomib and less cardiotoxic than carfilzomib.[2]

Ixazomib is currently the only oral proteasome inhibitor being used in treating multiple myeloma, so all interprofessional healthcare team members, including physicians, specialists, advanced practice practitioners, nursing staff, and pharmacists, should be aware of this drug, its indication, dosing, adverse event profile, potential drug-drug interactions, and requisite monitoring. Due to increasing use and the many adverse effects of ixazomib, the interprofessional team must monitor patients diligently, irrespective of their specific discipline. Clinicians must remember to monitor patients' liver function tests and platelet and neutrophil counts. The healthcare team should coordinate their activities and share information for patients on ixazomib if they are experiencing any rashes, feeling unwell, diarrhea, or other possible adverse reactions that dose modifications or other therapeutic alterations can be made in time. This interprofessional approach will increase the potential for patients to achieve success with their triple therapy, including dexamethasone and lenalidomide, and optimize outcomes in multiple myeloma cases.